Is GRAIL, Inc. (GRAL) Halal?

NASDAQ Healthcare United States $2.0B
✗ NOT HALAL
Confidence: 90/100
GRAIL, Inc. (GRAL) is Not Halal under AAOIFI Standard 21. While the debt ratio of 3.4% is acceptable, the cash and interest-bearing securities ratio of 37.7% exceeds the 30% threshold. GRAIL, Inc. operates in the Healthcare sector.

Shariah Screening — 5 Standards

Based on financial data from December 2025

Standard Debt Ratio Cash Ratio Receivables Income Status
AAOIFI 3.4%
/ 30%
37.7%
/ 30%
1.2%
/ 30%
21.29%
/ 5%
✗ NOT HALAL
DJIM 3.4%
/ 33%
37.7%
/ 33%
1.2%
/ 33%
21.29%
/ 5%
✗ NOT HALAL
MSCI 2.3%
/ 33%
25.6%
/ 33%
0.8%
/ 33%
21.29%
/ 5%
✗ NOT HALAL
S&P 3.4%
/ 33%
37.7%
/ 33%
1.2%
/ 33%
21.29%
/ 5%
✗ NOT HALAL
FTSE 2.3%
/ 33%
25.6%
/ 33%
0.8%
/ 50%
21.29%
/ 5%
✗ NOT HALAL

Financial Highlights

EPS
$-11.11
P/B Ratio
0.8
EV/EBITDA
-3.0
EV: $1.1B
Revenue
$147M
Growth: 14.0%
Current Ratio
12.0

Profitability

Gross Margin 48.5%
Operating Margin -285.4%
Net Margin -277.5%
Return on Equity (ROE) -16.1%
Return on Assets (ROA) -11.3%

Cash Flow & Balance Sheet

Operating Cash Flow-$299M
Free Cash Flow-$300M
Total Debt$55M
Debt-to-Equity2.1
Current Ratio12.0
Total Assets$2.9B

Price & Trading

Last Close$52.16
50-Day MA$74.47
200-Day MA$65.95
Avg Volume1.3M
52-Week Range
$20.44
$118.84

About GRAIL, Inc. (GRAL)

CEO
Mr. Robert P. Ragusa
Employees
910
Website
Sector
Healthcare
Industry
Diagnostics & Research
Country
United States
Exchange
NASDAQ
Market Cap
$2.0B
Currency
USD

GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.

Related Halal Stocks in Healthcare

Frequently Asked Questions

Is GRAIL, Inc. (GRAL) halal to invest in?

Based on our screening using AAOIFI Standard 21 (the strictest methodology), GRAIL, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.

What is GRAIL, Inc.'s debt ratio?

GRAIL, Inc.'s debt ratio is 3.4% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 2.3%.

What are GRAIL, Inc.'s key financial metrics?

GRAIL, Inc. has a market capitalization of $2.0B, and revenue of $147M. The company maintains a gross margin of 48.5% and a net margin of -277.5%. Return on equity stands at -16.1%.

How often is the screening data updated?

Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.

Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.